Novel compound, and pharmaceutical composition comprising same as active ingredient

A compound represented by Chemical Formula 1 below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

• in Chemical Formula 1,
• X1 to X4 are each independently N or C;
• Y is N, S, or O;
• R1 is C1-C10 alkyl, C3-C20 cycloalkyl, C2-C20 heterocycloalkyl, a 3- to 10-membered cyclic aromatic group, a 3- to 10-membered heterocyclic aromatic group, —CO—(C1-C6 alkyl), or —CO-(halogen-substituted or unsubstituted C6-C12 aryl), and
• at least one H of R1 is substituted with halogen, a cyano group, halogen-substituted or unsubstituted C6-C12 aryl, or halogen-substituted or unsubstituted C5-C12 heteroaryl;
• when all of X1 to X4 are C, R2 is hydrogen, halogen, or C1-C5 alkyl, and when one or more of X1 to X4 are N, R2 is hydrogen;
• R3 and R4 are linked to each other to form a 5- or 6-membered ring, wherein at least one H in the ring is substituted with —OH, —NH2, dimethylamine, —NH—(C1-C5 alkyl), —NH—(C1-C5 alkoxy), —NH—COCH3, —NH—SO2CH3, C1-C5 alkyl, or C1-C5 alkoxy, and
• when R3 and R4 do not form a ring, R4 is hydrogen or C1-C5 alkyl, R3 is C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 heterocycloalkyl, —CH2—(C3-C6 cycloalkyl), —CH2—(C2-C6 heterocycloalkyl), or —CH2-(3- to 6-membered heterocyclic aromatic group), at least one H of R3 is substituted with —OH, C1-C5 alkyl, acetyl, C1-C5 alkoxy, —COCF3, or —SO2CH3;
• and
• the heterocycloalkyl, heterocyclic group, and heteroaryl each independently include one or more hetero atoms selected from the group consisting of N, O, P, and S.